Skip to main content
Home
  • ALL Specialities ALL Specialities
    Home
    Home

    Error message

    • Deprecated function: Return type of DatabaseStatementBase::execute($args = [], $options = []) should either be compatible with PDOStatement::execute(?array $params = null): bool, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2246 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
    • Deprecated function: Return type of DatabaseStatementEmpty::current() should either be compatible with Iterator::current(): mixed, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
    • Deprecated function: Return type of DatabaseStatementEmpty::next() should either be compatible with Iterator::next(): void, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
    • Deprecated function: Return type of DatabaseStatementEmpty::key() should either be compatible with Iterator::key(): mixed, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
    • Deprecated function: Return type of DatabaseStatementEmpty::valid() should either be compatible with Iterator::valid(): bool, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
    • Deprecated function: Return type of DatabaseStatementEmpty::rewind() should either be compatible with Iterator::rewind(): void, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).

    Jeff Craven

    Article

    Banning indoor tanning devices could save lives and money

    Author:
    Jeff Craven
    Publish date: February 20, 2020

    Banning indoor tanning in the United States, Canada, and Europe could result in 187,481 fewer deaths from melanoma and save $5.7 billion.

    • Read More

    News

    Some relevant financial conflicts go undisclosed in ACR guidelines

    Author:
    Jeff Craven
    Publish date: February 18, 2020

    More than one-third of industry payments that were directly relevant to guidelines’ recommendations were undisclosed.

    • Read More

    News

    Palliative care improves QoL for patients with Parkinson’s disease and related disorders

    Author:
    Jeff Craven

    Randomized trial results support efforts to integrate palliative care into care for patients with Parkinson’s disease and related disorders.

    • Read More

    News

    Consider allergic contact dermatitis in children with AD with disease flares, new rash

    Author:
    Jeff Craven
    Publish date: February 7, 2020

    ORLANDO – “The take-home message here is that pediatric contact dermatitis is common, much more common than a lot of people realize.”

    • Read More

    News

    Measles, scarlet fever among infectious diseases to watch for in 2020

    Author:
    Jeff Craven
    Publish date: February 5, 2020

    ORLANDO – In 2019, data on the safety and effectiveness of the recombinant herpes zoster vaccine in immunocompromised patients became available....

    • Read More

    News

    Systemic therapy options for pediatric skin diseases are improving

    Author:
    Jeff Craven
    Publish date: January 31, 2020

    ORLANDO – Some systemic therapies are off label “but used all the time” for dermatologic diseases in pediatrics.

    • Read More

    News

    Be ready for patient questions on sunscreen safety, SPF choice

    Author:
    Jeff Craven
    Publish date: January 30, 2020

    ORLANDO – Which SPF to choose and the impact of sunscreen on vitamin D are among the issues patients may be asking about.

    • Read More

    News

    Dermatologists are uniquely suited to help sexual-, gender-minority patients

    Author:
    Jeff Craven
    Publish date: January 28, 2020

    ORLANDO – Dr. Landriscina encouraged attendees to take the information they learned in the session and “run with it.”

    • Read More

    News

    Adult survivors of childhood cancer are experiencing fewer major cardiac events

    Author:
    Jeff Craven
    Publish date: January 21, 2020

    Reduced radiation exposure is a likely contributor to the improved cardiovascular outcomes.

    • Read More

    News

    Adolescent alcohol, opioid misuse linked to risky behaviors

    Author:
    Jeff Craven
    Publish date: January 9, 2020

    Binge drinking in high school may predict risky driving behaviors for years after graduation.

    • Read More

    News

    Dual e-cigarette and combustible tobacco use compound respiratory disease risk

    Author:
    Jeff Craven
    Publish date: December 30, 2019

    E-cigarettes have been promoted as a safer alternative to combustible tobacco.

    • Read More

    News

    Well-tolerated topical capsaicin formulation reduces knee OA pain

    Author:
    Jeff Craven
    Publish date: December 18, 2019

    ATLANTA – A new vehicle formulation improves tolerability of capsaicin treatment.

    • Read More

    News

    ACR and EULAR release first classification criteria for IgG4-related disease

    Author:
    Jeff Craven
    Publish date: December 17, 2019

    In two validation cohorts, the criteria had specificities of 97.8%-99.2% and sensitivities of 82.0%-85.5%.

    • Read More

    News

    VEDOSS study describes predictors of progression to systemic sclerosis

    Author:
    Jeff Craven
    Publish date: December 12, 2019

    ATLANTA – When Raynaud’s phenomenon is present, risk for progression is best predicted by the presence of puffy fingers, disease-specific...

    • Read More

    News

    Tofacitinib improves disease activity in patients with polyarticular-course JIA

    Author:
    Jeff Craven
    Publish date: December 11, 2019

    ATLANTA – The phase 3 trial looked at flare rate out to 44 weeks after patients first met response criteria following 18 weeks of open-label...

    • Read More

    Pages

    • « first
    • …
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • …
    • last »

    Privacy Policy

    Terms of Use

    Editorial Policy

    Cookie Policy

    Ad Policy

    Medscape Customer Support

    Frequently Asked Questions

     

    Advertise with MDedge

    See more with MDedge! See our Other Publications

    MDedge: Keeping You Informed. Saving You Time.

    Copyright  © 2023 Frontline Medical Communications Inc., 283-299 Market Street, 2 Gateway Center, 4th Floor, Newark, NJ 07102. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

    • All Specialties
      • MDedge Home
      • Cardiology
      • Clinician Reviews
      • Dermatology
      • Emergency Medicine
      • Endocrinology/Diabetes
      • Family Medicine
      • Federal Practitioner
      • Gastroenterology
      • Hematology/Oncology
      • Infectious Disease
      • Internal Medicine
      • Neurology
      • Obstetrics And Gynecology
      • Pediatrics
      • Psychiatry
      • Pulmonology
      • Rheumatology
      • Surgery
    • MDedge Home
    • Cardiology
    • Clinician Reviews
    • Dermatology
    • Emergency Medicine
    • Endocrinology/Diabetes
    • Family Medicine
    • Federal Practitioner
    • Gastroenterology
    • Hematology/Oncology
    • Infectious Disease
    • Internal Medicine
    • Neurology
    • Obstetrics And Gynecology
    • Pediatrics
    • Psychiatry
    • Pulmonology
    • Rheumatology
    • Surgery